Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 11.17% is 61% below its 5-year average of 28.76%, near the high end of its 5-year range (-1892.19%–67.57%).
103.36% above its 12-month average of -332.38%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 65.69%.
GROSS MARGIN
11.17%
GROSS MARGIN AVG TTM
-332.38%
GROSS MARGIN AVG 3Y
51.45%
GROSS MARGIN AVG 5Y
28.76%
GROSS MARGIN AVG 10Y
16.41%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+103.36%
CURRENT VS 3Y AVG
-78.29%
CURRENT VS 5Y AVG
-61.16%
CURRENT VS 10Y AVG
-31.94%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-73.01%
vs the sector median at left
Insight Molecular Diagnostics Inc.
Market Cap
$109.14M
Gross Margin
11.17%
TTM Avg
-332.38%
3Y Avg
51.45%
5Y Avg
28.76%
Market Cap
$110.30M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$107.17M
Gross Margin
33.94%
TTM Avg
48.53%
3Y Avg
56.75%
5Y Avg
59.91%
Market Cap
$107.09M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
2.35%
Market Cap
$106.98M
Gross Margin
83.37%
TTM Avg
83.81%
3Y Avg
82.64%
5Y Avg
80.50%
Market Cap
$106.96M
Gross Margin
46.49%
TTM Avg
23.25%
3Y Avg
11.62%
5Y Avg
7.75%
Market Cap
$106.93M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$112.57M
Gross Margin
67.34%
TTM Avg
64.03%
3Y Avg
72.89%
5Y Avg
33.80%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $109.14M | 11.17% | -332.38% | 51.45% | 28.76% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.30M | 0.00% | 0.00% | 0.00% | 0.00% |
| Apyx Medical Corporation (APYX)vs › | $107.17M | 33.94% | 48.53% | 56.75% | 59.91% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.09M | 0.00% | 0.00% | 0.00% | 2.35% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | 83.37% | 83.81% | 82.64% | 80.50% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $106.96M | 46.49% | 23.25% | 11.62% | 7.75% |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | 0.00% | 0.00% | 0.00% | 0.00% |
| Immunic, Inc. (IMUX)vs › | $106.52M | 0.00% | 0.00% | 0.00% | 0.00% |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | 67.34% | 64.03% | 72.89% | 33.80% |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.94M | 0.00% | 0.00% | 50.00% | 33.33% |
Gross Margin
11.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 65.69% |
| 2026-03-31 | -1892.19% |
| 2025-12-31 | 43.55% |
| 2025-09-30 | 53.46% |
| 2025-06-30 | 67.57% |
| 2025-03-31 | 61.97% |
| 2024-12-31 | 40.04% |
| 2024-09-30 | 43.48% |
| 2024-06-30 | 48.08% |
| 2024-03-31 | 25.57% |
| 2023-12-31 | -30.25% |
| 2023-09-30 | 57.81% |
| 2023-06-30 | 58.75% |
| 2023-03-31 | 3.37% |
| 2022-12-31 | -1.46% |
| 2022-09-30 | -401.49% |
| 2022-06-30 | 13.08% |
| 2022-03-31 | 65.00% |
| 2021-12-31 | 38.14% |
| 2021-09-30 | -88.01% |
| 2021-06-30 | -19.41% |
| 2021-03-31 | 7.03% |
| 2020-12-31 | -42.35% |
| 2020-09-30 | -8.29% |
| 2020-06-30 | -155.24% |
| 2020-03-31 | -981.25% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
